Sign in to continue:

Wednesday, March 4th, 2026

Synergy CHC Corp. Announces Termination of Brand License Agreement with Gravity Pharma – SEC 8-K Filing March 2026




Synergy CHC Corp. Files Form 8-K: Key Details for Investors

Synergy CHC Corp. Files Form 8-K: Key Details for Investors

Overview

On March 3, 2026, Synergy CHC Corp. (Nasdaq: SNYR) filed a Form 8-K with the U.S. Securities and Exchange Commission. The report is a standard “Current Report” under Section 13 or 15(d) of the Securities Exchange Act of 1934, with the event date recorded as February 27, 2026. The filing was signed by CEO Jack Ross.

Key Points from the Report

  • Form Type: 8-K (Current Report) – This is typically used to disclose events that are material to shareholders or may impact the company’s value.
  • Company Details:

    • Name: Synergy CHC Corp.
    • Address: 865 Spring Street, Westbrook, ME 04092
    • Phone: (207) 321-2350
    • Exchange: Nasdaq Stock Market LLC
    • Trading Symbol: SNYR
    • Security Registered: Common Stock, par value \$0.00001 per share
  • Emerging Growth Company Status: Synergy CHC Corp. has indicated it is not an emerging growth company.
  • Other Events: The Form 8-K was filed under the “Other Events” category, which means the company is reporting something outside the standard categories (like changes in control, results of operations, etc.).
  • No Amended Filings: The filing is not an amendment to a previous submission.
  • No Pre-commencement Communications: The company checked “no” to written communications, soliciting materials, and pre-commencement tender offers, indicating no public solicitation related to mergers or acquisitions is underway.

Potentially Price Sensitive Information

Materiality: Based on the contents of this Form 8-K, there is no price sensitive or material event disclosed that would be expected to impact the share value of Synergy CHC Corp. The filing is categorized under “Other Events” with no explicit mention of new business developments, financial results, mergers, acquisitions, leadership changes, or regulatory actions.

Shareholders should note: The absence of any specific material disclosures in this filing means there are no immediate actions or developments reported that would typically influence the company’s stock price.

  • The company is in compliance with the Exchange Act and maintains its Nasdaq listing.
  • No shareholder action or response is required based on this filing.
  • No strategic shifts or changes in corporate structure are indicated.

Signature

The filing was duly authorized and signed by Jack Ross, Chief Executive Officer of Synergy CHC Corp.

Conclusion

Investor Impact: There are currently no material developments reported in this 8-K filing that would affect investors or the market valuation of Synergy CHC Corp. The filing appears to fulfill routine compliance or administrative obligations.


Disclaimer: This article is a summary and interpretation of the public SEC filing by Synergy CHC Corp. It does not constitute investment advice, and investors should review the full filing and consult their financial advisor before making any investment decisions. No material event or news has been disclosed that would be expected to affect the company’s share price.




View Synergy CHC Corp. Historical chart here



Amicus Therapeutics 2025 Annual Report: Pipeline, Products, Risks, Competition, and Regulatory Overview

Amicus Therapeutics 2025 Annual Report: Key Investor Insights and Price-Sensitive Updates Amicus Therapeutics 2025 Annual Report: Key Investor Insights and Price-Sensitive Updates Overview Amicus Therapeutics, Inc. (NASDAQ: FOLD) has released its Annual Report for...

Essex Property Trust, Inc. 2025 Annual Report: Real Estate Investment Trust (REIT) Financials, Investments, and Portfolio Overview

Essex Property Trust, Inc. 2025 Annual Report: Key Highlights and Investor Insights Introduction Essex Property Trust, Inc. (NYSE: ESS), a leading Real Estate Investment Trust (REIT) focused on high-quality apartment communities in the West...

Lightbridge Corp Achieves Key Nuclear Fuel Milestones and Reports Strong Fiscal 2025 Financial Results

Lightbridge Corporation FY2025 Results & Business Update Lightbridge Corporation Delivers Strong Business Update and Fiscal Year 2025 Financial Results Key Highlights from Lightbridge’s 2025 Annual Report Major Progress in Nuclear Fuel Development: Lightbridge, in...

   Ad